MX2011010782A - Compuestos agonistas del receptor 5-ht4 para el tratamiento de trastornos cognitivos. - Google Patents

Compuestos agonistas del receptor 5-ht4 para el tratamiento de trastornos cognitivos.

Info

Publication number
MX2011010782A
MX2011010782A MX2011010782A MX2011010782A MX2011010782A MX 2011010782 A MX2011010782 A MX 2011010782A MX 2011010782 A MX2011010782 A MX 2011010782A MX 2011010782 A MX2011010782 A MX 2011010782A MX 2011010782 A MX2011010782 A MX 2011010782A
Authority
MX
Mexico
Prior art keywords
treatment
cognitive disorders
receptor agonist
agonist compounds
compounds
Prior art date
Application number
MX2011010782A
Other languages
English (en)
Spanish (es)
Inventor
Robert Murray Mckinnell
David Beattie
Fei Shen
Jacqueline A M Smith
Ray Chang
Original Assignee
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Inc filed Critical Theravance Inc
Publication of MX2011010782A publication Critical patent/MX2011010782A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/468-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2011010782A 2009-04-13 2010-04-12 Compuestos agonistas del receptor 5-ht4 para el tratamiento de trastornos cognitivos. MX2011010782A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16874109P 2009-04-13 2009-04-13
US29255910P 2010-01-06 2010-01-06
PCT/US2010/030760 WO2010120695A2 (en) 2009-04-13 2010-04-12 5-ht4 receptor agonist compounds for treatment of cognitive disorders

Publications (1)

Publication Number Publication Date
MX2011010782A true MX2011010782A (es) 2012-01-20

Family

ID=42237213

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011010782A MX2011010782A (es) 2009-04-13 2010-04-12 Compuestos agonistas del receptor 5-ht4 para el tratamiento de trastornos cognitivos.

Country Status (24)

Country Link
US (2) US8404711B2 (enExample)
EP (1) EP2419104B1 (enExample)
JP (1) JP2012523437A (enExample)
KR (1) KR20120017421A (enExample)
CN (2) CN105832735A (enExample)
AU (1) AU2010236734B2 (enExample)
BR (1) BRPI1013777A8 (enExample)
CA (1) CA2758321A1 (enExample)
CY (1) CY1119800T1 (enExample)
DK (1) DK2419104T3 (enExample)
ES (1) ES2654930T3 (enExample)
HR (1) HRP20180018T1 (enExample)
HU (1) HUE038141T2 (enExample)
IL (1) IL215660A0 (enExample)
LT (1) LT2419104T (enExample)
MX (1) MX2011010782A (enExample)
NO (1) NO2419104T3 (enExample)
PL (1) PL2419104T3 (enExample)
PT (1) PT2419104T (enExample)
RU (1) RU2569056C2 (enExample)
SI (1) SI2419104T1 (enExample)
SM (1) SMT201800036T1 (enExample)
WO (1) WO2010120695A2 (enExample)
ZA (1) ZA201107490B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
CA2744278C (en) 2008-11-19 2015-09-08 Envivo Pharmaceuticals, Inc. Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
RU2011150248A (ru) * 2009-05-11 2013-06-20 Энвиво Фармасьютикалз, Инк. Лечение когнитивных расстройств с определенными рецепторами альфа-7 никотиновой кислоты в комбинации с ингибиторами ацетилхолинэстеразы
CN103221411B (zh) 2010-05-17 2016-05-11 富瑞姆制药公司 (R)-7-氯-N-(奎宁环-3-基)苯并[b]噻吩-2-甲酰胺盐酸盐单水合物的晶型
CA2872005A1 (en) 2012-05-08 2013-11-14 Forum Pharmaceuticals, Inc. Methods of maintaining, treating or improving cognitive function
US10874701B2 (en) 2012-08-16 2020-12-29 University-Industry Cooperation Group Of Kyung Hee University Lactic acid bacteria capable of preventing and/or treating senescence and dementia
US20150306158A1 (en) 2012-08-16 2015-10-29 University-Industry Cooperation Group Of Kyung Hee University Lactic acid bacteria capable of preventing and/or treating senescence and dementia
MX385719B (es) 2017-05-24 2025-03-18 H Lundbeck As Combinacion de un antagonista del receptor 5-ht6 y un inhibidor de acetilcolinesterasa para su uso en el tratamiento de la enfermedad de alzheimer en una subpoblacion de pacientes portadores de alelos apoe4
SG11201909359YA (en) 2017-06-01 2019-11-28 Eisai R&D Man Co Ltd Pharmaceutical composition comprising pde9 inhibitor
EP3632431A4 (en) 2017-06-02 2020-06-03 FUJIFILM Toyama Chemical Co., Ltd. Agent for preventing or treating brain atrophy
SI3661518T1 (sl) * 2017-07-31 2025-01-31 Alfasigma S.P.A. Načini zdravljenja simptomov gastropareze z zdravilom velusetrag

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1311272T3 (da) * 2000-03-03 2007-02-26 Eisai R&D Man Co Ltd Hidtil ukendte fremgangsmåder hvor der anvendes cholinesteraseinhibitorer
TWI351282B (en) * 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
US7598265B2 (en) 2004-09-30 2009-10-06 Epix Delaware, Inc. Compositions and methods for treating CNS disorders
TWI377206B (en) * 2005-04-06 2012-11-21 Theravance Inc Crystalline form of a quinolinone-carboxamide compound
MY147756A (en) * 2005-05-25 2013-01-15 Theravance Inc Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists

Also Published As

Publication number Publication date
LT2419104T (lt) 2018-02-12
ES2654930T3 (es) 2018-02-15
JP2012523437A (ja) 2012-10-04
NO2419104T3 (enExample) 2018-04-07
EP2419104B1 (en) 2017-11-08
RU2011146032A (ru) 2013-05-20
HUE038141T2 (hu) 2018-10-29
PL2419104T3 (pl) 2018-04-30
EP2419104A2 (en) 2012-02-22
WO2010120695A2 (en) 2010-10-21
PT2419104T (pt) 2018-01-31
DK2419104T3 (en) 2018-02-05
BRPI1013777A2 (pt) 2016-04-05
CA2758321A1 (en) 2010-10-21
HRP20180018T1 (hr) 2018-02-09
IL215660A0 (en) 2012-01-31
US20100261752A1 (en) 2010-10-14
CN102395371A (zh) 2012-03-28
SI2419104T1 (en) 2018-03-30
SMT201800036T1 (it) 2018-03-08
AU2010236734A8 (en) 2012-02-16
US8404711B2 (en) 2013-03-26
WO2010120695A3 (en) 2010-12-02
ZA201107490B (en) 2012-06-27
AU2010236734A1 (en) 2011-11-03
CN105832735A (zh) 2016-08-10
KR20120017421A (ko) 2012-02-28
US20140057939A1 (en) 2014-02-27
AU2010236734B2 (en) 2015-06-11
CY1119800T1 (el) 2018-06-27
RU2569056C2 (ru) 2015-11-20
BRPI1013777A8 (pt) 2017-09-19

Similar Documents

Publication Publication Date Title
MX2011010782A (es) Compuestos agonistas del receptor 5-ht4 para el tratamiento de trastornos cognitivos.
MX2020012825A (es) Compuestos multiciclicos y metodos de uso de los mismos.
MX2009008253A (es) Derivados de 2-aminopiridina utiles como inhibidores de cinasa.
MX2010002732A (es) Inhibidores de f1f0-atpasa y metodos relacionados.
ME01532B (me) Jedinjenja
MY161656A (en) Therapeutic use of diaminophenothiazines
IL200793A0 (en) Aminopyrimidines, compositions comprising the same and use thereof for inhibiting protein kinases
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
PL2134704T3 (pl) Związki i kompozycje pełniące rolę modulatorów aktywności GPR119
MX2009009592A (es) Aminopiridinas utiles como inhibidores de proteinas cinasas.
IN2012DN02177A (enExample)
IN2012DN02471A (enExample)
SI2176252T1 (sl) 2,3-dihidrobenzo(1,4)dioksin-2-ilmetilni derivati kot alfa2C antagonisti za uporabo v zdravljenju bolezni perifernega in centralnega živčnega sistema
MX2009006345A (es) Compuestos utiles como inhibidores de proteina cinasa.
IL193080A0 (en) Methods, compositions, and kits for the treatment of musculoskeletal disorders and symptoms associated therewith
MX2011013032A (es) Inhibidores de fosfatidilinositol 3-cinasa.
MX2011011950A (es) Composiciones de dexmedetomidina sublinguales y metodos de uso de las mismas.
MY147649A (en) Benzimidazole derivatives useful in treatment of vallinoid receptor trpv1 related disorders
MX2010007490A (es) Preparacion de derivados de sulfamida.
TW200800958A (en) N-substituted-azacyclylamines as histamine-3 antagonists
MX340807B (es) Nuevas composiciones para prevenir y/o tratar trastornos degenerativos del sistema nervioso central.
MX2010006206A (es) Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
MY150600A (en) Use of opioid antagonists for treating urinary retention
MX2009003645A (es) Azaciclilaminas n-sustituidas como antagonistas de histamina-3.
MY150931A (en) Substituted oxazolidinones and their use

Legal Events

Date Code Title Description
FG Grant or registration